

Wim Pj Witjes

List of Publications by Citations

Source: <https://exaly.com/author-pdf/4119767/wim-pj-witjes-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63

papers

3,527

citations

28

h-index

59

g-index

76

ext. papers

4,383

ext. citations

5.4

avg, IF

4.6

L-index

#	Paper	IF	Citations
63	MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. <i>New England Journal of Medicine</i> , 2018 , 378, 1767-1777	59.2	1250
62	Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. <i>European Urology</i> , 2019 , 75, 410-418	10.2	193
61	4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer. <i>European Urology</i> , 2000 , 38, 706-13	10.2	179
60	Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer. <i>Urology</i> , 1997 , 49, 65-9	1.6	146
59	Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. <i>European Urology</i> , 1998 , 34, 169-75	10.2	142
58	Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. <i>BJU International</i> , 1997 , 80, 597-605	5.6	105
57	Original Articles: Bladder Cancer: A Randomized Study of Intravesical Mitomycin C, Bacillus Calmette-Guerin Tice and Bacillus Calmette-Guerin RIVM Treatment in pTa-pT1 Papillary Carcinoma and Carcinoma in Situ of the Bladder. <i>Journal of Urology</i> , 1995 , 153, 929-933	2.5	105
56	Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS). <i>European Urology</i> , 2015 , 67, 482-91	10.2	92
55	Long-term follow-up of an EORTC randomized prospective trial comparing intravesical bacille Calmette-Guérin-RIVM and mitomycin C in superficial bladder cancer. EORTC GU Group and the Dutch South East Cooperative Urological Group. European Organisation for Research and Treatment of Cancer Genitourinary Tract Cancer Collaborative Group. <i>Urology</i> , 2000 , 55, 102-10	1.6	84
54	Predicting Response to Intravesical Bacillus Calmette-Guérin Immunotherapy: Are We There Yet? A Systematic Review. <i>European Urology</i> , 2018 , 73, 738-748	10.2	77
53	Transurethral resection of the prostate vs high-energy thermotherapy of the prostate in patients with benign prostatic hyperplasia: long-term results. <i>British Journal of Urology</i> , 1998 , 81, 259-64		76
52	RESULTS OF A RANDOMIZED PHASE III TRIAL OF SEQUENTIAL INTRAVESICAL THERAPY WITH MITOMYCIN C AND BACILLUS CALMETTE-GUERIN VERSUS MITOMYCIN C ALONE IN PATIENTS WITH SUPERFICIAL BLADDER CANCER. <i>Journal of Urology</i> , 1998 , 160, 1668-1672	2.5	75
51	High energy thermotherapy versus transurethral resection in the treatment of benign prostatic hyperplasia: results of a prospective randomized study with 1 year of followup. <i>Journal of Urology</i> , 1997 , 158, 120-5	2.5	67
50	Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. <i>European Urology</i> , 2011 , 60, 713-20	10.2	66
49	Use of neoadjuvant chemotherapy for muscle-invasive bladder cancer is low among major European centres: results of a feasibility questionnaire. <i>European Urology</i> , 2012 , 61, 1070-1	10.2	64
48	The correlation between prostate volume, transition zone volume, transition zone index and clinical and urodynamic investigations in patients with lower urinary tract symptoms. <i>BJU International</i> , 1997 , 80, 84-90	5.6	55
47	Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer. <i>European Urology</i> , 2008 , 53, 984-91	10.2	53

46	A randomised prospective study comparing intravesical instillations of mitomycin-C, BCG-Tice, and BCG-RIVM in pTa-pT1 tumours and primary carcinoma in situ of the urinary bladder. Dutch South-East Cooperative Urological Group. <i>European Journal of Cancer</i> , 1993 , 29A, 1672-6	7.5	48
45	The International Continence Society "Benign Prostatic Hyperplasia" Study: international differences in lower urinary tract symptoms and related bother. <i>Journal of Urology</i> , 1997 , 157, 1295-300 ²⁻⁵	2.5	47
44	The international terazosin trial: a multicentre study of the long-term efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. The ITT Group. <i>European Urology</i> , 1996 , 30, 369-76	10.2	44
43	Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group. <i>Urology</i> , 1995 , 45, 581-6	1.6	38
42	Improved reliability of uroflowmetry investigations: results of a portable home-based uroflowmetry study. <i>BJU International</i> , 1996 , 78, 385-90	5.6	36
41	Intracutaneous and intravesical immunotherapy with keyhole limpet hemocyanin compared with intravesical mitomycin in patients with non-muscle-invasive bladder cancer: results from a prospective randomized phase III trial. <i>Journal of Clinical Oncology</i> , 2012 , 30, 2273-9	2.2	33
40	Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis. <i>Urology</i> , 1997 , 49, 197-205; discussion 205-6	1.6	31
39	A New Long Acting Formulation of the Luteinizing Hormone-Releasing Hormone Analogue, Goserelin: Results of Studies in Prostate Cancer. <i>Journal of Urology</i> , 1996 , 155, 1352-1354	2.5	31
38	Quantitative assessment of uroflow: is there a circadian rhythm?. <i>Urology</i> , 1997 , 50, 221-8	1.6	29
37	Results of a European comparative randomized study comparing oral bropirimine versus intravesical BCG treatment in BCG-naive patients with carcinoma in situ of the urinary bladder. European Bropirimine Study Group. <i>European Urology</i> , 1999 , 36, 576-81	10.2	29
36	Urodynamic and Clinical Effects of Terazosin Therapy in Patients with Symptomatic Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 1996 , 155, 1317-1323	2.5	28
35	Variability of Clinical and Pressure-Flow Study Variables After 6 Months of Watchful Waiting in Patients with Lower Urinary Tract Symptoms and Benign Prostatic Enlargement. <i>Journal of Urology</i> , 1996 , 156, 1026-1034	2.5	26
34	Three-month depot of goserelin acetate: clinical efficacy and endocrine profile. Dutch South East Cooperative Urological Group. <i>Urology</i> , 1996 , 48, 894-900	1.6	25
33	Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial	10.2	23
32	Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation. <i>World Journal of Urology</i> , 2016 , 34, 173-80	4	22
31	Urodynamic and clinical effects of noninvasive and minimally invasive treatments in elderly men with lower urinary tract symptoms stratified according to the grade of obstruction. <i>Urology</i> , 1997 , 50, 55-61	1.6	15
30	Clinical implications of the rise and fall of prostate specific antigen after laser prostatectomy. <i>BJU International</i> , 1996 , 78, 742-6	5.6	14
29	Application of sublingual buprenorphine in combination with naproxen or paracetamol for post-operative pain relief in cholecystectomy patients in a double-blind study. <i>Acta Anaesthesiologica Scandinavica</i> , 1992 , 36, 323-7	1.9	14

28	Patient-reported Quality of Life in Patients with Primary Metastatic Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate in a Prospective Randomised Clinical Trial; Data from the HORRAD Trial. <i>European Urology</i> , 2021 , 79, 188-197	10.2	13
27	Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy. <i>BJU International</i> , 2014 , 114, 193-201	5.6	12
26	Computerized artifact detection and correction of uroflow curves: towards a more consistent quantitative assessment of maximum flow. <i>European Urology</i> , 1998 , 33, 54-63	10.2	12
25	Review on the simultaneous determination of total prostate-specific antigen and free prostate-specific antigen. <i>Prostate</i> , 1996 , 29, 48-57	4.2	12
24	Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care. <i>Public Health Genomics</i> , 2015 , 18, 349-58	1.9	11
23	A randomized study comparing epirubicin in a 4-weekly versus a weekly intravenous regimen in patients with metastatic, hormone resistant, prostatic carcinoma: effects on health related quality of life. <i>World Journal of Urology</i> , 2003 , 21, 177-82	4	11
22	The use of ultrasensitive prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy. <i>British Journal of Urology</i> , 1996 , 77, 418-22		11
21	A method for estimating within-patient variability in maximal urinary flow rate adjusted for voided volume. <i>Urology</i> , 2002 , 59, 368-72	1.6	10
20	Perioperative chemotherapy in muscle-invasive bladder cancer: overview and the unmet clinical need for alternative adjuvant therapy as studied in the MAGNOLIA trial. <i>European Urology</i> , 2014 , 65, 509-11	10.2	9
19	Therapies used in prostate cancer patients by European urologists: data on indication with a focus on expectations, perceived barriers and guideline compliance related to the use of bisphosphonates. <i>Urologia Internationalis</i> , 2012 , 89, 30-8	1.9	8
18	Current status of neoadjuvant therapy in localized prostate cancer. <i>Prostate</i> , 1995 , 27, 297-303	4.2	8
17	The AVOCAT study: Bicalutamide monotherapy versus combined bicalutamide plus dutasteride therapy for patients with locally advanced or metastatic carcinoma of the prostate-a long-term follow-up comparison and quality of life analysis. <i>SpringerPlus</i> , 2016 , 5, 653		5
16	Medical therapy versus transurethral resection of the prostate (TURP) for the treatment of symptomatic benign prostatic enlargement (BPE): a cost minimisation analysis. <i>World Journal of Urology</i> , 2019 , 37, 873-878	4	5
15	Automated Bone Scan Index as an Imaging Biomarker to Predict Overall Survival in the Zometa European Study/SPCG11. <i>European Urology Oncology</i> , 2021 , 4, 49-55	6.7	5
14	The value of neoadjuvant therapy in localized prostate cancer. <i>International Journal of Urology</i> , 1995 , 2, 1-5	2.3	4
13	Similar rates of exponential decrease in serum concentrations of free prostate-specific antigen (PSA), PSA complexed to alpha-1-antichymotrypsin, and human glandular kallikrein 2 (hK2) in prostate cancer patients treated with GnRH-analogues. <i>Prostate</i> , 2001 , 47, 14-20	4.2	3
12	Contemporary use of phytotherapy in patients with lower urinary tract symptoms due to benign prostatic hyperplasia: results from the EVOLUTION European registry. <i>World Journal of Urology</i> , 2021 , 39, 2661-2667	4	3
11	ZOLEDRONIC ACID FOR THE PREVENTION OF BONE METASTASES IN HIGH RISK PROSTATE CANCER PATIENTS. A RANDOMISED, OPEN LABEL, MULTICENTRE STUDY OF THE EUROPEAN ASSOCIATION OF UROLOGY (EAU) IN COOPERATION WITH THE SCANDINAVIAN PROSTATE CANCER GROUP (SPCG) AND THE ARBEITSGEMEINSCHAFT UROLOGISCHE ONKOLOGIE (AUO). <i>European Urology Supplements</i> , 2008 , 7, 232	0.9	2

10	Re: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer. <i>European Urology</i> , 2016 , 70, 204-5	10.2	2
9	Incidence of Nocturia in Men with Lower Urinary Tract Symptoms Associated with Benign Prostatic Enlargement and Outcomes After Medical Treatment: Results from the Evolution European Association of Urology Research Foundation Prospective Multinational Registry. <i>European Urology</i> , 2016 , 70, 178-187	5.1	2
8	PD16-08 EVOLUTION: A EUROPEAN REGISTRY EVALUATING MANAGEMENT PRACTICES OF PHARMACOLOGICALLY TREATED PATIENTS WITH LUTS ASSOCIATED WITH BPH. SYMPTOMATIC IMPROVEMENT, PROGRESSION AND TREATMENT DISCONTINUATION RESULTS. A COMPARISON BETWEEN EUROPEAN COUNTRIES.. <i>Journal of Urology</i> , 2015 , 193, 178-187	2.5	1
7	Computerised assessment of maximum urinary flow: an efficient, consistent and valid approach. <i>European Urology</i> , 2002 , 41, 206-13; discussion 213	10.2	1
6	Reply to Emre Karabay and İker Tülay Letter to the Editor re: Treatment of High-grade Non-muscle-invasive Bladder Carcinoma by Standard Number and Dose of BCG Instillations Versus Reduced Number and Standard Dose of BCG Instillations: Results of the European Association of Urology Research Foundation Randomised Phase III Clinical Trial "NUMBUS". <i>Eur Urol</i> . In press	10.2	1
5	MP35-06 THE PREVALENCE OF URGENCY IN PATIENTS WITH LOWER URINARY TRACT SYMPTOMS DUE TO BENIGN PROSTATIC ENLARGEMENT. ANALYSIS OF THE EVOLUTION REGISTRY.. <i>Journal of Urology</i> , 2016 , 195, 178-187	2.5	1
4	Quality of life with pharmacological treatment in patients with benign prostatic enlargement: results from the Evolution European Prospective Multicenter Multi-National Registry Study. <i>World Journal of Urology</i> , 2021 , 39, 517-526	4	1
3	Adjuvant recMAGE-A3 Immunotherapy After Cystectomy for Muscle-invasive Bladder Cancer: Lessons Learned from the Phase 2 MAGNOLIA Clinical Trial. <i>European Urology Focus</i> , 2019 , 5, 849-852	5.1	0
2	Bone Scan Index as an imaging biomarker to predict overall survival in the Zeus/SPCG11 study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16599-e16599	2.2	
1	A European Registry Evaluating Symptomatic Effectiveness of Pharmacologically Treated Patients with Lower Urinary Tract Symptoms due to Benign Prostatic Enlargement: Lessons Learned. <i>Journal of Urology</i> , 2021 , 205, 1145-1152	2.5	